In addition, the improvement of pulmonary vascular physiology observed in in vitro and in vivo models of pulmonary hypertension following PDE5 inhibition has provided the rationale to recommend also PDE5 as a target for the treatment of pulmonary hypertension and respiratory distress [122, 123]. The gene discussed is PDE5A; the disease is pulmonary hypertension.